fda compounding semaglutide crackdown news today 2025 The is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday You may have seen the

A bioreducible N -oxide-based probe for photoacoustic imaging of hypoxia

doi: 10.1016/j.xcrm.2021.100424 83 MullerAJLauraM-NPrendergastGC

The potential benefits of tirzepatide for substance use disorders, if confirmed through rigorous research, could represent a valuable addition to existing treatment approaches

Utilization efficiency of human Milk oligosaccharides by human-associated Akkermansia is strain dependent

Moreover, patients without preexisting conditions, such as moderate-to-severe CKD and chronic ischemic heart disease, showed more pronounced risk reductions (HR = 0.69 and HR = 0.66, respectively) than their counterparts (HR = 0.75 and HR = 0.80, respectively)